Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
461-480 of 2,251 trials

Triple Negative Breast Cancer: Capecitabine and Pembrolizumab Study

We are studying the effects of capecitabine combined with pembrolizumab in patients with triple negative breast cancer after surgery and chemotherapy. This trial aims to see if this combination improves survival rates compared to standard treatments.

Triple Negative Breast Cancer6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Dostarlimab for Advanced Cancer with dMMR/MSI

We are studying whether the immunotherapy dostarlimab can help patients with advanced non-colorectal and non-endometrial cancers live longer compared to standard treatments. This trial focuses on those with specific genetic markers in their tumors.

dMMR/MSI Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology

Advanced Melanoma: IMC-F106C Plus Nivolumab

We are studying a new treatment combination for people with previously untreated advanced melanoma. The goal is to see if it helps patients live longer and have better outcomes compared to standard treatment.

Advanced Melanoma1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyOncology

Metastatic Non-Small Cell Lung Cancer: ONC-392 vs. Docetaxel

We are studying a new treatment, ONC-392, to see if it helps patients with metastatic non-small cell lung cancer who have progressed on immunotherapy. The goal is to compare its effectiveness and safety against the standard treatment, docetaxel.

Metastatic Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Perianal Crohn’s Disease: FAPi-PET Imaging Study

We are exploring whether a new imaging method can help visualize and measure healing in fistulas for patients with perianal Crohn’s disease. This study may also help predict how well treatments are working.

Crohn's DiseaseFistulizing Crohn's Disease≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyInternal Medicine

Hidradenitis Suppurativa: Bimekizumab for Teens

We are studying how the drug bimekizumab works and its safety for treating moderate to severe hidradenitis suppurativa in pubertal children and adolescents.

Hidradenitis SuppurativaConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesAllergologyDermatology

Non-Hodgkin Lymphoma: Epcoritamab with Anti-Cancer Agents

We are studying the safety and tolerability of Epcoritamab combined with other anti-cancer medications for people with Non-Hodgkin Lymphoma. This trial aims to see how well this combination works and to find the best dose for future studies.

B-cell Non-Hodgkin's LymphomaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Influenza Vaccine Study for Hematological Cancer Patients

We are testing whether a high-dose flu vaccine works better than a standard dose in patients with hematological cancers. This study aims to improve vaccine effectiveness and understand immune responses in these patients.

Hematological Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyInfectious Diseases

Cancer Treatment: Immune Markers and Side Effects

We are exploring blood markers in cancer patients to identify signs of side effects from checkpoint inhibitor treatments. This research may help improve safety and management of these therapies.

Solid Tumor>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineOncology

DLBCL Treatment: Dexrazoxane for Heart Protection

We are studying whether dexrazoxane can help prevent heart problems in patients with diffuse large B-cell lymphoma receiving chemotherapy. This trial will also compare treatment responses and monitor any side effects.

Diffuse Large B-Cell Lymphoma3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCardiologyOncology

Nutrition Timing After Major Abdominal Surgery

We are comparing early versus delayed nutrition support for patients recovering from major emergency abdominal surgery. The goal is to see which approach may lower the risk of infections after surgery.

Major Emergency Abdominal Surgery≤3 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesGastroenterology

Acute Myeloid Leukemia: Cobicistat with Venetoclax and Azacitidine

We are studying a new treatment combination for patients with acute myeloid leukemia who cannot receive intensive chemotherapy. This trial aims to see if adding cobicistat to venetoclax and azacitidine improves survival and treatment outcomes.

Acute Myeloid Leukaemia3-6 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineOncology

Metastatic Breast Cancer: Sacituzumab Govitecan Study

We are analyzing how well sacituzumab govitecan works for patients with advanced breast cancer. The study will also assess safety and explore biomarkers that may predict treatment response.

Locally Advanced or Metastatic Hormone Receptor Positive Breast Cancer6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Multiple Sclerosis: Annual vs. Semi-Annual Ocrelizumab Infusions

We are comparing the effects of annual and semi-annual infusions of ocrelizumab in patients with active multiple sclerosis. The goal is to see which schedule better prevents disease activity over two years.

Multiple Sclerosis1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesNeurology

Chronic Rhinosinusitis: Mepolizumab and Nasal Polypectomy Study

We are investigating whether combining Mepolizumab with in-office nasal polypectomy can improve quality of life for patients with chronic rhinosinusitis. The study will assess symptom relief and safety over time.

Chronic Rhinosinusitis with Nasal Polyps6-12 monthsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesAllergologyOtolaryngology

Memory Disorders: Evaluating Tau PET Imaging

We are studying whether tau PET can improve diagnosis for patients with memory problems. This trial compares its effectiveness to more common and affordable diagnostic tools.

Mild Cognitive Impairment and Dementia1-2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementNeurology

Follicular Lymphoma: Mosunetuzumab and Lenalidomide Study

We are evaluating a new combination treatment for people with untreated follicular lymphoma to see if it works better than standard chemotherapy. This study aims to improve patient outcomes and quality of life.

Follicular Lymphoma>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Chronic Lymphocytic Leukemia: Venetoclax and Acalabrutinib Treatment

We are studying a combination of venetoclax and acalabrutinib for patients with CLL who have relapsed after previous treatment. The goal is to see if this combination can help achieve better disease control and improve quality of life.

Chronic Lymphocytic LeukemiaPatients with Relapsed CLL>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesHematologyOncology

Erosive Esophagitis: NEXIUM for Kids

We are studying whether NEXIUM can help maintain healing in children aged 1 to 11 with erosive esophagitis. This trial also looks at how well the medication works and any symptoms during treatment.

Erosive Esophagitis6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Bacterial Brain Abscess: Oral vs. IV Antibiotics

We are studying whether oral antibiotics are as effective as IV antibiotics for treating bacterial brain abscesses. This trial will help us understand the best treatment options and their impact on recovery and quality of life.

Brain Abscess>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesNeurology